Our top pick for
Building a portfolio
Jaws Acquisition Corp is a shell companies business based in the US. Jaws Acquisition shares (JWS) are listed on the NYSE and all prices are listed in US Dollars.
|Latest market close||$14.51|
|52-week range||$9.95 - $16.95|
|50-day moving average||$13.48|
|200-day moving average||$13.67|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-06-25)||N/A|
|1 month (2021-06-04)||-3.84%|
|3 months (2021-04-05)||8.53%|
|6 months (2021-01-05)||2.26%|
|1 year (2020-07-02)||N/A|
|2 years (2019-07-02)||N/A|
|3 years (2018-07-02)||N/A|
|5 years (2016-07-02)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||0%|
|Return on equity TTM||-9999999%|
|Market capitalisation||$1.3 billion|
TTM: trailing 12 months
There are currently 5.1 million Jaws Acquisition shares held short by investors – that's known as Jaws Acquisition's "short interest". This figure is 29.6% up from 3.9 million last month.
There are a few different ways that this level of interest in shorting Jaws Acquisition shares can be evaluated.
Jaws Acquisition's "short interest ratio" (SIR) is the quantity of Jaws Acquisition shares currently shorted divided by the average quantity of Jaws Acquisition shares traded daily (recently around 447696.56992084). Jaws Acquisition's SIR currently stands at 11.37. In other words for every 100,000 Jaws Acquisition shares traded daily on the market, roughly 11370 shares are currently held short.
However Jaws Acquisition's short interest can also be evaluated against the total number of Jaws Acquisition shares, or, against the total number of tradable Jaws Acquisition shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Jaws Acquisition's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Jaws Acquisition shares in existence, roughly 60 shares are currently held short) or 0.1065% of the tradable shares (for every 100,000 tradable Jaws Acquisition shares, roughly 107 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Jaws Acquisition.
Find out more about how you can short Jaws Acquisition stock.
We're not expecting Jaws Acquisition to pay a dividend over the next 12 months.
Jaws Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more operating businesses or entities. The company was incorporated in 2019 and is based in Miami Beach, Florida. Jaws Acquisition Corp. is a subsidiary of Jaws Sponsor LLC. .
Everything we know about the Huake Holding Biology Co IPO, plus information on how to buy in.
Everything we know about the Outbrain IPO, plus information on how to buy in.
Everything we know about the Duolingo IPO, plus information on how to buy in.
Everything we know about the Elicio Therapeutics IPO, plus information on how to buy in.
Everything we know about the Paltalk IPO, plus information on how to buy in.
Everything we know about the Instructure Holdings IPO, plus information on how to buy in.
Everything we know about the Ipsidy IPO, plus information on how to buy in.
Everything we know about the ScoutCam IPO, plus information on how to buy in.
Everything we know about the Candel Therapeutics IPO, plus information on how to buy in.
Everything we know about the Xponential Fitness IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.